INTRODUCTION
Protective immunity against different classes of pathogens is dependent upon generation of distinct types of immune responses mediated and coordinated by T helper 1 (Th1), Th2, and Th17 effector CD4 + T cells. The signals promoting differentiation of naive CD4 + T cells into a particular T helper cell subset are provided by distinct sets of secreted and membrane bound cytokines elaborated upon triggering of innate immune sensors of infection (e.g., Toll-like receptors, inflammasomes, RIG-I, and MDA5) displayed by antigen-presenting cells (APCs). Activation of members of the STAT transcription factor family downstream of corresponding cytokine receptors is critical for generation of the effector CD4 + T cell subsets. For example, activation of STAT3 downstream of IL-6, IL-23, and IL-21 receptors is required for efficient generation of highly inflammatory Th17 cells essential for protective immunity against yeast, fungi, and extracellular bacteria (Adamson et al., 2009; Littman and Rudensky, 2010; Xu and Cao, 2010) . Th17 cells specific for self-antigens and, possibly, for commensal microbiota have been also implicated in autoimmune diseases such as inflammatory bowel disease, arthritis, and psoriasis (Ahern et al., 2008; McKenzie et al., 2006) . In both immunity to infection and autoimmunity, effector CD4 + T cells act foremost as critical amplifiers and ''recruiters'' of the appropriate types of inflammatory immune responses mediated by cells of both the innate and adaptive immune systems (Littman and Rudensky, 2010) .
In addition to a response mode tailored to protect against a particular type of pathogen, a successful immune defense strategy requires intricate negative regulation to restrict host tissue damage caused by the inflammation. Besides cellintrinsic downmodulation of signaling through antigen-specific and innate receptors, these mechanisms include elaboration of inhibitory soluble mediators by immune effector cells acting in both an autocrine and paracrine manner. Among these mediators, IL-10, which can be produced by multiple immune cell types, plays a particularly prominent role in curtailing immunemediated inflammation in the context of infection, allergy, and autoimmunity (Moore et al., 2001; Saraiva and O'Garra, 2010) .
The negative regulation afforded by immune effector cells themselves is complemented by suppression of inflammatory responses by regulatory T (Treg) cells. These cells, characterized by the expression of the X chromosome-encoded transcription factor Foxp3, are vital for preventing autoimmunity and immune-mediated inflammation elicited by commensal microbiota and by pathogens, especially during chronic infection. Treg cell deficiency resulting from deletion or loss-of-function mutations of the Foxp3 gene causes a fatal lympho-and myeloproliferative inflammatory syndrome characterized by massive cytokine storm including sharply increased amounts of Th1, Th2, and Th17 cell cytokines (Fontenot et al., 2003) . Likewise, ablation of Treg cells in adult healthy mice leads to augmented generation of Th1, Th2, and Th17 cells and death within 2 weeks from highly aggressive inflammatory lesions in a variety of organs (Kim et al., 2007) . These observations suggest a possibility that Treg cells are able to control different types of the immune response by tailoring their suppressive function to a particular inflammatory environment. In support of this notion, in Treg cells, expression of T-bet and IRF-4 (transcription factors involved in Th1 and Th2 cell differentiation, respectively) facilitates Treg cell-mediated suppression of the corresponding type of response (Koch et al., 2009; Zheng et al., 2009 ). Along the same lines, Treg cell-specific deletion of STAT3, a transcription factor necessary for Th17 cell differentiation, results in a fatal Th17 cell-driven colitis . In Treg cells, activated STAT3 and Foxp3 cooperatively regulate a subset of genes, which probably endows Treg cells with the ability to suppress Th17 cell-mediated inflammation ). STAT3 can be activated downstream of receptors for several proinflammatory cytokines including IL-6 and IL-23, which serve as critical inducers of Th17 cell responses, as well as IL-10, known to restrain Th17 cell-mediated inflammation (Gu et al., 2008; McGeachy et al., 2007; Yen et al., 2006) . These observations raise a question as to whether the ability of Treg cells to suppress Th17 cell-mediated inflammation is imparted upon sensing proinflammatory (IL-6 and IL-23) or anti-inflammatory (IL-10) cues. The former scenario would suggest that Treg cellmediated suppression represents negative feedback regulation induced by an inflammatory environment. In contrast, the latter scenario implies that Treg cells amplify negative regulators elicited by immune effector cells. Here, we demonstrate that IL-10R, but not IL-6R or IL-23R, was required for Treg cell-mediated suppression of spontaneous Th17 cell-driven colitis. Thus, in analogy with amplification of effector immune responses by distinct types of Th cells, Treg cells act as amplifiers of negative regulatory circuits of immune effector cells to restrain Th17 cellmediated inflammation.
RESULTS

IL-10 Elicits Potent STAT3 Phosphorylation in Treg Cells
STAT3 activation elicited by IL-6, IL-23, and IL-21 is indispensable for differentiation of activated T cells into Th17 effector cells. In addition to these proinflammatory cytokines, STAT3 phosphorylation can be induced by the anti-inflammatory cytokine IL-10, known to oppose Th17 cell responses (O'Shea and Murray, 2008) . Our recent studies showed that in suppressive Treg cells, STAT3 plays an essential role for their ability to suppress pathogenic Th17 cell responses ). Thus, we sought to explore whether pro-or anti-inflammatory cytokine signaling confers upon Treg cells the ability to restrain Th17 cell-dependent inflammation. Because thresholds and consequences of STAT3 activation elicited by different cytokines differ between various cell types, we first assessed STAT3 phosphorylation in response to titrated amounts of IL-6 and IL-10 in conventional naive CD4 + Foxp3 À T cells and Treg cells. Amounts of phosphorylated STAT3 (pSTAT3; Y705) were determined via flow cytometric or immunoblot analyses. We found that stimulation of naive CD4 + and CD8 + T cells with IL-6 induced markedly higher pSTAT3 as compared to IL-10. In contrast, IL-10 was a more potent inducer of STAT3 phosphorylation in Treg cells as compared to naive T cells ( Figures 1A-1C ). The total STAT3 amounts were not changed upon cytokine treatment. These findings indicate that the proinflammatory cytokine IL-6 is more effective in inducing STAT3 activation in naive T cells, whereas in Treg cells, the antiinflammatory cytokine IL-10 triggers more efficient STAT3 phosphorylation. Furthermore, basal amounts of pSTAT3 in unstimulated T cells and Treg cells after IL-23 treatment were not different (data not shown). Several factors can account for these differences including varying surface expression of the corresponding cytokine receptors and altered expression of either positive or negative regulators of STAT3 activation. Regardless of the mechanism underlying the contrasting pattern of Treg and naive T cell responsiveness to IL-6 and IL-10, these results suggest that Treg cells are poised to sense IL-10 and that IL-10R on Treg cells plays a pivotal role in their function.
Impaired STAT3 Phosphorylation in IL-10R-but Not IL-6R-Deficient Treg Cells
To directly explore this possibility, we induced Treg cell-specific ablation of IL-10R and IL-6R by breeding mice harboring a conditional allele encoding IL-10Ra (Il10ra fl ) or IL-6Ra (Il6ra fl ) chain with Foxp3 Cre mice (Pils et al., 2010; Wunderlich et al., 2010; Rubtsov et al., 2008) . Foxp3 Cre Il10ra fl/fl and Foxp3 Cre Il6ra fl/fl mice were born at an expected Mendelian ratio and efficiency of deletion was confirmed by quantitative PCR ( Figure S1 available online). We then tested the assumption that IL-10R plays a nonredundant role in STAT3 activation in Treg cells by analyzing pSTAT3 in MACS-purified CD4 + CD25 + Treg cells isolated from spleens and lymph nodes of healthy 3-to 4-week-old Foxp3 Cre Il10ra fl/fl or littermate control Foxp3 Cre Il10ra wt/wt mice. IL-10R-deficient Treg cells showed reduced pSTAT3 as compared to littermate controls. In contrast, no differences in pSTAT3 amounts were observed in IL-6R-deficient as compared to IL-6R-sufficient Treg cells ( Figure 1D ). These results indicated that IL-10R signaling is an important contributor to STAT3 activation in Treg cells in accordance with the in vitro analysis of STAT3 phosphorylation in Treg cells.
Mice Harboring IL-10R-Deficient Treg Cells Developed Severe Immune-Mediated Colitis
Although Foxp3 Cre Il10ra fl/fl mice appeared healthy up to 8-10 weeks of age, these mice developed clinical symptoms of immune-mediated colitis later in life. At $13-14 weeks of age, they exhibited failure to thrive, splenomegaly, and pronounced enlargement of mesenteric lymph nodes ( Figure 2A ). Despite unchanged or even somewhat reduced numbers of T cells in the lymph nodes and spleen, we observed a marked increase in activated CD44 hi CD62L lo CD4 + T cells in these mice as compared to littermate controls ( Figures 2B-2D ). Moreover, these mice developed weight loss, rectal prolapse, and colon thickening and succumbed to the disease by 18-20 weeks of age ( Figure 2G ). These clinical manifestations are hallmarks of inflammatory bowel disease (IBD), which was confirmed by histological examination of the intestinal tissues ( Figure 2H ). In particular, the colon of the affected mice exhibited marked thickening of the mucosa with dense lymphoid and lesser neutrophilic infiltration, crypt loss and abscessation, regions of glandular hyperplasia with irregular gland formation, and increased mitotic figures. In the most severely affected mice, the inflammation was transmural extending to the attached mesentery ( Figure 2I ). Unlike colitic Foxp3 Cre Il10ra fl/fl mice, where essentially all Treg cells lacked IL-10R, heterozygote female Foxp3 Cre/wt Il10ra fl/fl mice, harboring both IL-10R-sufficient and -deficient Treg cells, remained disease-free ( Figure S2 ). The heightened activation of CD4 + T cells in the presence of IL-10R-deficient Treg cells was not due to diminished numbers, but rather the frequency and absolute numbers of Treg cells were increased in Foxp3 Cre Il10ra fl/fl mice (Figures 2E and 2F ). Furthermore, the IL-10R-sufficient and -deficient Treg cells expressed similar amounts of Foxp3 ( Figure 2E ), excluding diminished Foxp3 expression as an explanation for the pathology in Foxp3 Cre Il10ra fl/fl mice.
IL-10R Deficiency Does Not Impair Stability of Foxp3 Expression in Treg Cells
A recent study suggested that upon adoptive transfer of naive CD4 + T cells and Treg cells into lymphopenic hosts, innate immune cell production of IL-10 in the recipients is required to maintain Foxp3 expression (Murai et al., 2009) . In this study, Treg cells lacking IL-10R lost Foxp3 expression and thus their suppressor function under inflammatory conditions and, hence, severe colitis commenced in lymphopenic hosts. Because Foxp3 Cre Il10ra fl/fl mice develop similar pathology, it was plausible that the phenotype observed in our studies was due to a loss of Foxp3 expression in the absence of IL-10R. Although flow cytometric analysis did not reveal any difference in Foxp3 amounts on per cell basis between Foxp3 Cre Il10ra fl/fl mice and control littermates ( Figure 2E) , it was still possible that loss of Foxp3 expression by some IL-10R-deficient Treg cells was masked by proliferation of newly generated Treg cells. To address this important caveat, we employed inducible ablation of the Il10ra fl allele in Treg cells by using Cre-ERt2 recombinase and assessed Foxp3 expression (Rubtsov et al., 2010) . For these experiments, we crossed the Il10ra fl mice to knockin Foxp3 Cre-ERt2 mice that express a triple fusion protein of the enhanced green fluorescent protein (eGFP) with Cre recombinase and mutated human estrogen receptor ligand-binding domain (ERt2) under control of the Foxp3 gene. These mice were equipped with a Cre-mediated recombination reporter allele containing a loxP site-flanked STOP cassette followed by a DNA sequence encoding yellow fluorescent protein (YFP) knocked into the ubiquitously expressed ROSA26 locus (R26Y). Treatment of these mice with tamoxifen induced Cre-ERt2-mediated IL-10R ablation and YFP tagging upon excision of the STOP cassette. Genetic labeling of Foxp3expressing cells with YFP via inducible recombination avoids the continuous incorporation into the labeled population of cells that transiently upregulate Foxp3 and affords assessment of Foxp3 stability in differentiated Treg cells. Thus, Foxp3 Cre-ERt2 Il10ra fl/fl R26Y and littermate control mice were administered tamoxifen and analyzed 3 and 12 weeks later for Foxp3 expression in YFP + CD4 + T cells. We found that IL-10R ablation did not affect Foxp3 expression within splenic and lymph node cells and that essentially all YFP + tagged cells expressed unaltered amounts of Foxp3 at both time points ( Figure 3A) . These results were also confirmed by intracellular staining for Foxp3 and flow cytometric analysis of FACS-purified YFP + cells at both time points ( Figure 3B ). Moreover, analysis of Foxp3 mRNA expression in the sorted YFP + cells by quantitative PCR (qPCR) also did not detect a measurable loss of Foxp3 in IL-10R-ablated Treg cells. As expected, expression of IL-10R mRNA were substantially lower in YFP + Treg cells isolated from Foxp3 Cre-ERt2 Il10ra fl/fl R26Y mice as compared to the control animals ( Figure 3C ). Further characterization of the YFP-tagged IL-10R-deficient Treg cells did not reveal changes in expression of Th1, Th2, and Th17 cellspecific transcription factors and corresponding cytokines ( Figure S3 ). These findings effectively exclude a loss of Foxp3 expression as an explanation for the observed inability of IL-10R-deficient Treg cells to suppress intestinal inflammation.
Unimpaired Function of IL-6R-and IL-23R-Deficient Treg Cells In Vivo
In contrast to immunosuppressive effects of IL-10, IL-6 signaling on T cells has been suggested to be critical for mediating as well as sustaining enteric inflammation (Fasnacht et al., 2009 ). To identify whether IL-6 signaling plays a similar role in Treg cells, we examined Foxp3 Cre Il6ra fl/fl mice. IL-6R ablation in Treg cells did not result in noticeable changes in cytokine production or activation status and numbers of T cells and other immune cell types including granulocytes, macrophages, B cells, NK cells, and dendritic cells ( Figure S4 ; data not shown). Accordingly, phenotype of Treg cells in Foxp3 Cre Il6ra fl/fl mice was indistinguishable from that in littermate controls and both groups of mice remained healthy.
To assess potential role for IL-23R in Treg cell function, we generated mixed bone marrow (BM) chimeras by transferring T cell-depleted BM cells from IL-23R-deficient (Il23r À/À ) or -sufficient Ly5.2 B6 mice mixed with BM cells from Ly5.1 + Foxp3 À mice into lethally irradiated (900 rads) Rag2 À/À recipients. In these experimental chimeric mice, all Treg cells lacked IL-23R expression. Irradiated Rag2 À/À recipients reconstituted with Foxp3 À BM cells alone, which served as a positive control for immunemediated lesions, died within 5-6 weeks after BM transfer (data not shown). In contrast, IL-23R-deficient Treg cells appeared fully functional and (Il23r À/À + Foxp3 À ) / Rag2 À/À BM chimeras were healthy and devoid of measurable signs of T cell activation, lymphoproliferation, and immune-mediated pathology ( Figure S5 ). Thus, in contrast to IL-10R ablation, IL-6R or IL-23R deficiency in Treg cells did not have noticeable effect on their function. Recent work has demonstrated that inflammatory Th1 and Th17 cell responses can facilitate both colitis development and progression (Brand, 2009) . Therefore, we assessed T cell production of different effector cytokines in Foxp3 Cre Il10ra fl/fl mice. We observed elevated production of Th17 cell-associated Figures 4B and 4C) . In contrast, production of Th1 and Th2 cell-associated cytokines IFN-g, IL-4, and IL-5 was comparable in Foxp3 Cre Il10ra fl/fl and littermate control mice. Production of other cytokines such as IL-2 was also unaffected ( Figures 4B and 4C) . Notably, IL-10Rdeficient Foxp3 + Treg cells did not produce any of these cytokines ( Figure 4B ). Thus, IL-10R-deficient Treg cells were capable of keeping Th1 and Th2 cell responses in check.
IL-10R-Deficient Treg Cells Fail to Suppress Th17 Cell Responses In Vivo
These results were consistent with the idea that only a distinct aspect of the suppressor program was impaired in IL-10R-deficient Treg cells, whereas their general suppressive capacity was intact. This notion was supported by unimpeded ability of IL-10R-deficient Treg cells to suppress proliferative responses of naive T cells in vitro ( Figure 5A ). To examine suppressor function in vivo, we cotransferred flow cytometry-purified IL-10Rdeficient or -sufficient Ly5.2 + Treg cells and effector Ly5.1 + CD4 T cells from Foxp3 À mice into Rag2 À/À recipients. Prior to transfer, the effector CD4 + T cell population was heavily skewed toward Th1 cells, but also contained Th2 and Th17 polarized cells ( Figure 5B ). Effector Foxp3 À T cells transferred alone into Rag2 À/À recipients induced fatal systemic multiorgan autoimmune syndrome associated with lymphoproliferation and increased Th1, Th2, and Th17 cell cytokine production, similar to that observed in unmanipulated Foxp3 À mice. Cotransfer of IL-10R-deficient Treg cells and Foxp3 À effector T cells resulted only in dysregulated Th17 cell responses as evidenced by increased frequencies and absolute numbers of IL-17-producing Ly5.1 + Foxp3 À CD4 + T cells in recipient mice ( Figure 5C ) and a colitis similar in severity to that seen in Foxp3 Cre Il10ra fl/fl mice ( Figure 5D ). Despite failure to suppress Th17 cell-mediated inflammation, IL-10R-deficient Treg cells were able to restrain lymphoproliferation as well as Th1 and Th2 cell responses (Figure 5C) . In contrast, all autoimmune and clinical IBD manifestations were abrogated upon cotransfer of IL-10R-sufficient Treg cells with only mild subclinical and nonfatal colitis noted histologically ( Figure 5D ). Thus, these results suggest that IL-10Rdeficient Treg cells are selectively impaired in their ability to control inflammatory Th17 cell responses and that this impairment leads to fatal colitis.
IL-10R Signaling Facilitates IL-10 Production by Treg Cells
Although Treg cells employ multiple mechanisms of suppression, IL-10 produced by Treg cells plays an important role in preventing colonic inflammation. Mice with Treg cell-specific ablation of IL-10 develop spontaneous colitis (Rubtsov et al., 2008) . Thus, it was plausible that IL-10 produced by immune effector cells elicited STAT3 phosphorylation in Treg cells, which in turn induced IL-10 production in these cells as well as other media-tors of suppression. STAT3 has recently been shown to directly bind to a diverse array of targets (Durant et al., 2010) . Thus, we examined STAT3 binding to regulatory elements of the Il10 gene in Treg cells. Indeed, we found that STAT3 binds at the Il10 locus in Treg cells ( Figure 6A ). To test whether IL-10R deficiency in Treg cells impairs their ability to produce IL-10, we examined IL-10 expression at the mRNA level in IL-10R-deficient and -sufficient Treg cells via qPCR. These experiments showed significantly diminished production of IL-10 by IL-10R-deficient Treg cells ( Figure 6B) . Thus, IL-10R signaling in Treg cells leads to STAT3-dependent expression of IL-10.
In aggregate, our studies implicate sensing of anti-inflammatory cytokine IL-10, but not proinflammatory IL-6 and IL-23, by Treg cells as an essential facilitator of their suppressor function. IL-10 produced by diverse immune effector cells induces activation of STAT3 in Treg cells and thereby facilitates their ability to suppress Th17 cell responses, which includes IL-10 production by Treg cells. These results suggest that Treg cells suppress Th17 cell-mediated inflammation by acting as amplifiers of negative regulatory mechanisms elaborated by immune effector cells.
DISCUSSION
IL-17-and IL-22-producing Th17 cells mediate protection against mycobacterial, fungal, and bacterial infections. Under physiologic conditions, Th17 cells are found predominantly in the small and large intestine and associated lymphoid tissues where they facilitate production of antimicrobial peptides, enforce integrity of the epithelial barrier, and recruit and activate granulocytes and macrophages to restrain pathogenic bacteria (Weaver et al., 2007) . Recent studies demonstrated a critical role of certain components of commensal flora in induction of Th17 cell responses. In germ-free (GF) mice devoid of commensal flora, Th17 cells are essentially undetectable but are prominently present upon colonization of GF mice with a single commensal microorganism, segmented filamentous bacterium (Ivanov et al., 2009) . Th17 cells play a prominent role not only in resistance against intestinal pathogens such as Shigella or Citrobacter , but also in autoimmune and inflammatory disorders in the gastrointestinal tract including Crohn's disease and ulcerative colitis (Ahern et al., 2008) . The preferential generation of Th17 cells in the small and large intestine-associated lymphoid tissues and draining lymph nodes is due to high expression of factors supporting Th17 cell differentiation. These factors include IL-1, TGF-b, and STAT3-signaling inflammatory cytokines IL-6, IL-21, and IL-23 (Korn et al., 2009) . A complete block of Th17 cell differentiation in the absence of STAT3 illustrates a critical role for the latter three cytokines (Mathur et al., 2007; Yang et al., 2007) .
Intestinal homeostasis requires restraint of highly inflammatory Th17 cells by a variety of cell-intrinsic and -extrinsic negative regulatory mechanisms. Among mechanisms limiting Th17 cell responses, another STAT3-signaling cytokine IL-10 plays a prominent role (Gu et al., 2008; Li and Flavell, 2008; McGeachy et al., 2007) . IL-10 is a powerful negative regulator of the immunemediated inflammation with a broad range of target cell types, primarily of hematopoietic origin (Jankovic et al., 2010) . IL-10 has been implicated in limiting inflammation at environmental interfaces, in particular, in the gut and lung mucosa (Groux and Cottrez, 2003; Sun et al., 2009) . Germline IL-10 deficiency in mice or inability of T cells to produce IL-10 leads to immunemediated colitis (Roers et al., 2004) that is completely dependent on enteric microflora (Stehr et al., 2009) , defining a major tissueprotective role for IL-10. Not surprisingly, impaired IL-10 signaling has also been implicated in the pathogenesis of IBD, and recently mutations in the IL-10R genes have been described in two unrelated families with a heritable and poorly treatable form of Crohn's disease (Glocker et al., 2009) . Multiple immune effector cells, including T cells, B cells, macrophages, dendritic cells, NK cells, neutrophils, eosinophils, and mast cells, express IL-10 ( Saraiva and O'Garra, 2010) . In a naive mouse, B cells have been reported to constitute a dominant source of IL-10 in several lymphoid tissues, and B cellderived IL-10 plays a nonredundant role in restraining T cell responses . Unlike several other cell types where IL-10 plays an immunosuppressive function, IL-10 on B cells acts to prevent apoptosis and enhances proliferation, differentiation, and MHC II expression in addition to playing a role in regulation of Ig class switching (Sabat et al., 2010) . The differential activation of STAT3 observed in B cells upon IL-10 as opposed to IL-6 stimulation probably reflects the crucial role of IL-10 in B cell function.
Within the T cell subset, activated CD8 + T cells and all three main effector CD4 + T cell types (Th1, Th17, and Th2 cells) are capable of secreting IL-10 (Li and Flavell, 2008) . Thus, IL-10 production represents an essential negative feedback mechanism elaborated by immune effector cells to limit their activation.
In addition to immune effector T cells, suppressive Foxp3 À Tr1 and Foxp3 + Treg cells produce IL-10 in the small and large intestine. Recently, we demonstrated that expression of STAT3 in Treg cells is a prerequisite for their ability to suppress Th17 cell responses and that ablation of STAT3 in Treg cells results in fatal Th17 cell-mediated colitis ). Because STAT3 is required both for elaboration of inflammatory Th17 cell responses and for their suppression by Treg cells, two models of Treg cell-mediated control of Th17 cell inflammatory responses can be considered. First, Treg cells directly sense the inflammatory environment favoring Th17 cell differentiation, i.e., high amounts of IL-6 and IL-23, which activate STAT3 and thereby enable Treg cell-mediated suppression of Th17 celldependent inflammation. Alternatively, Treg cells respond to the anti-inflammatory mediator IL-10 produced by the immune effector cells. According to this scenario, Treg cells act as amplifiers of the negative regulatory mechanisms elaborated by immune effector cells in analogy to the aforementioned amplification of immune responses by effector T cell subsets. Our finding that IL-10R signaling in Treg cells was necessary for their suppression of Th17 cell responses, whereas IL-6R or IL-23R was dispensable, strongly argues in favor of the latter possibility. In addition, this finding suggests that the essential role for STAT3 in Treg cells for suppression of Th17 cell inflammation is dependent upon its phosphorylation downstream of cytokine receptors and subsequent changes in gene expression.
Colitis observed in Foxp3 Cre Il10ra fl/fl mice was similar to that observed in mice harboring STAT3-deficient Treg cells, suggesting that IL-10 is the predominant activator of STAT3 signaling in Treg cells. Like STAT3-deficient Treg cells, IL-10R-deficient Treg cells also fail to suppress Th17 cell responses, whereas no increases in Th1 or Th2 cell cytokines were noted. Nevertheless, clinical colitis progression in the presence of IL-10R-deficient Treg cells was slower than that in the presence of STAT3-deficient Treg cells, implying that an additional STAT3 signaling cytokine(s) can contribute to some extent to STAT3 activation in Treg cells.
Recent work has suggested that Treg cells may lose Foxp3 expression in inflammatory settings and these ''ex-Treg'' cells can contribute to pathology (Murai et al., 2010; Zhou et al., 2009) . In particular, IL-10 signaling was shown to be necessary for Treg cell stability in an experimental colitis model. A prominent loss of Foxp3 was observed upon transfer of purified Il10rb À/À Treg cells together with naive CD4 + CD45RB hi T cells into lymphopenic recipients (Murai et al., 2009 ). However, we found similar Foxp3 protein expression in IL-10R-deficient and -sufficient Treg cells and increased numbers of Foxp3 + cells were present in Foxp3 Cre Il10ra fl/fl mice. Furthermore, we failed to detect loss of Foxp3 expression upon cotransfer of effector Foxp3 À cells and IL-10R-deficient Treg cells into lymphopenic recipients. Finally, we did not observe detectable loss of Foxp3 expression upon inducible deletion of IL-10R in Treg cells combined with the cell fate mapping approach via Foxp3 Cre-ERt2 and R26Y recombination reporter allele (Rubtsov et al., 2010) . These results indicate that despite loss of IL-10 signaling, Treg cells remain stable and that potential downregulation of Foxp3 cannot explain the inflammatory colitis observed with Treg cell-specific deletion of IL-10R. One possible explanation for discrepant results is that few contaminating Foxp3 À cells can rapidly expand in lymphopenic settings (Komatsu et al., 2009) and that this expansion in numbers can be further exacerbated by a lack of IL-10 signaling. Furthermore, these incongruent results can also be potentially dependent on whether Il10ra or Il10rb was utilized to inactivate IL-10 signaling. Whereas IL-10Ra, required for ligand binding, is unique to the IL-10R complex, IL-10Rb, essential to mediate downstream signaling, is shared between several members of the class II cytokine receptors such as IL-22R and IFN-lR family members (Pestka et al., 2004) . Although the expression and function of these receptors on Treg cells have not been characterized, it remains possible that functions of IL-10Rb unrelated to IL-10 signaling can account for this discordance. Although Treg cell-mediated suppression is not fully understood in mechanistic terms, various studies indicate that Treg cells utilize multiple means to accomplish suppression of different inflammatory responses (Shevach, 2009; Vignali et al., 2008) . Our observation that phosphorylated STAT3 binds to regulatory elements of the Il10 gene in Treg cells and that IL-10R deficiency in these cells is associated with drastically reduced IL-10 expression is indicative of a feed-forward IL-10 loop operating in Treg cells, i.e., IL-10 produced by variety of cellular sources augments its own production by Treg cells. Importantly, ablation of IL-10 in Treg cells leads to spontaneous colitis albeit less severe than that in Foxp3 Cre Stat3 fl/fl or Foxp3 Cre Il10ra fl/fl mice (Rubtsov et al., 2008) . Furthermore, impaired IL-10 signaling in effector T cells results in augmented Th17 cell but not Th1 cell responses, and Treg cells can restrain these Th17 cell responses in an IL-10dependent manner (Huber et al., 2011) . These observations corroborate our findings that reduced IL-10 production by IL-10R-deficient Treg cells is likely to affect Th17 but not other T cell responses.
Our studies indicate that Treg cell-mediated suppression of Th17 cell-driven pathology is facilitated by activation of STAT3 downstream of IL-10R engagement by IL-10. Subsequent induction of a STAT3-dependent Th17 cell-suppression program including IL-10 production by Treg cells can then result in dampening of this Th17 cell response. However, it is also possible that Treg cells can act on effector T cells to induce IL-10 expression (Kearley et al., 2005) . In either scenario, we suggest that Treg cells can act as amplifiers of negative regulatory mechanisms, such as IL-10, that are initially elaborated by immune effector cells upon their activation. This is in analogy with amplification of a particular type of innate and adaptive immune responses by a given effector CD4 + T cell type.
EXPERIMENTAL PROCEDURES
Animals
Foxp3 À , Foxp3 Cre , Foxp3 Cre-ERt2 , Rosa26 YFP , Il6ra fl , and Il10ra fl mice have been previously described (Fontenot et al., 2003; Pils et al., 2010; Rubtsov et al., 2008 Rubtsov et al., , 2010 Wunderlich et al., 2010) . IL-23R-deficient mice were kindly provided by V. Kuchroo (Harvard Medical School). C57BL/6J were purchased from the Jackson Laboratories (Bar Harbor, ME). All the mice were bred and housed in the specific-pathogen-free animal facility at the Memorial Sloan-Kettering Cancer Center and used in accordance with institutional guidelines. Tamoxifen (Sigma) was dissolved in olive oil (Fluka) to a final concentration of 40 mg/ml. Mice received three doses of tamoxifen (8 mg each) at days 0, 1, and 3 by oral gavage.
Reagents, Flow Cytometry, and Cell Isolation
Fluorophore-conjugated antibodies were purchased from BD-Biosciences and eBioscience. Stained cells were analyzed with a FACSCanto or LSRII flow cytometer (BD Biosciences) and data were analyzed with FlowJo soft-ware (Treestar). Intracellular Foxp3 staining was performed with Foxp3 mouse Treg cell staining kit (eBioscience). Flow cytometric analysis of pSTAT3 staining was performed according to manufacturer's instructions by immediate fixation with BD Phosflow Fix Buffer and Perm Buffer III (BD Biosciences). Cytokine staining was performed after stimulation of splenocytes with PMA (50 ng/ml) and ionomycin (500 ng/ml) for 4-6 hr in the presence of Golgi-Plug (BD Biosciences). All antibodies used for flow cytometry staining were purchased from eBioscience or BD Biosciences.
Single-cell suspensions from lymph nodes and spleen were generated by mechanical disruption. CD4 + CD25 À naive T cells and CD4 + CD25 + regulatory T cells were purified with MACS isolation kits (Miltenyi Biotec, Germany) according to the manufacturer's protocol. Foxp3-YFP + and Foxp3-YFP À cells were isolated by sorting on a FACS Aria cell sorter (BD Biosciences).
In Vitro Suppression Assays
For in vitro suppression assays, Treg cells and effector T cells were purified by positive selection with CD4-specific beads (Invitrogen) followed by FACS sorting. Antigen-presenting cells (APC) were prepared from wild-type C57BL/6J splenocytes by T cell depletion with Thy1-specific MACS beads. Effector T cells (2 3 10 4 cells/well) were cocultured with Treg cells at indicated ratios in the presence of irradiated (2000 rad) APCs (1 3 10 5 cells/well) and CD3 antibody (1 mg/ml) in 96-well plates for 60 hr and pulsed with 1 mCi 3 H-thymidine for additional 8-12 hr. Cell proliferation was measured with a scintillation counter. The data are presented as mean cpm 3 H-thymidine incorporation in triplicate cultures and standard deviation.
Immunoblot Analysis
Whole-cell extracts from MACS (Miltenyi)-purified CD4 + CD25 À and CD4 + CD25 + T cells or FACS-sorted CD4 + Foxp3 À and CD4 + Foxp3 + T cells were prepared with RIPA lysis buffer and subjected to immunoblot analysis with antibodies specific for STAT3 and pSTAT3 (Y705) (Cell Signaling Technologies).
Quantitative PCR
Total RNA was extracted with TriZOL reagent (Invitrogen) from FACS-purified IL-10R-sufficient and -deficient CD4 + YFP + Treg cells. cDNA was synthesized with SuperscriptIII Reverse Transcriptase (Invitrogen), followed by real-time PCR analysis (SYBR green; Applied Biosystems).
Histopathological Evaluation of Colitis
Samples of cecum and colon from 3-5 animals per group were fixed in 10% neutral buffered formalin and routinely processed for hematoxylin and eosin staining. Histological evaluation of colitis was performed as described previously (Burich et al., 2001) . In brief, the cecum, proximal, middle, and distal colon were scored by a pathologist on a 0-4 scale each for mucosal changes (erosion, ulceration, and/or hyperplasia), inflammation, and extent of section involvement. The total inflammation score (IBD score) was derived by summing the scores from the individual segments and subsequently the mean was derived for each experimental group.
Chromatin Immunoprecipitation
ChIP was performed as described previously (Zheng et al., 2007) . CD4 + CD25 + Treg cells from 6-to 8-month-old mice were isolated with Treg cell isolation kit (Miltenyi Biotec). Antibody to STAT3 was used from Cell Signaling Technology. Relative abundance of regions of interest in precipitated DNA was measured by qPCR with Power SYBR-Green PCR master mix (Applied Biosystems).
Statistical Methods
Unless otherwise noted, statistical analysis was performed with the Student's t test on individual biological replicates in Prism (GraphPad).
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